Location:
2751 Fort Amanda Road Lima, OH 45805
Phone:
567-529-9000
Fax:
567-529-9001
Working Hours:
Monday - Friday: 8.00am - 05.00pm

Darolutamide [Nubeqa] – (Androgen Receptor Inhibitor)

  • Home
  • Urologic Cancers
  • Darolutamide [Nubeqa] – (Androgen Receptor Inhibitor)

As a Center of Excellence, Crossroads Urology combines advanced technology with evidence-based protocols to deliver the highest standard of specialized care for our patients.

Call Us when you Need Help!
24/7 Support: +1 567-529-9000

Introduction

Darolutamide, sold under the trade name Nubeqa, is a next-generation androgen receptor inhibitor used to treat advanced prostate cancer. Known for its favorable safety profile, Darolutamide is particularly effective in non-metastatic castration-resistant prostate cancer (nmCRPC).

Purpose

  • Treats non-metastatic castration-resistant prostate cancer (nmCRPC).
  • Delays progression to metastatic disease while preserving quality of life.
  • Provides an effective option with fewer central nervous system side effects compared to other androgen receptor inhibitors.

How It Works

Darolutamide blocks the activity of androgen receptors in prostate cancer cells, preventing testosterone from fueling tumor growth. Its unique molecular structure minimizes penetration into the brain, reducing side effects such as fatigue and cognitive impairment.

Usage

  • Taken as an oral tablet, typically twice daily with food.
  • Combined with androgen deprivation therapy (ADT) to suppress testosterone production.
  • Regular monitoring of prostate-specific antigen (PSA) levels and imaging studies is recommended to assess efficacy.

Considerations

  • Common side effects include fatigue, joint pain, and rash.
  • Rare but serious side effects include liver dysfunction and cardiovascular events; routine blood tests are recommended to monitor for these risks.
  • Darolutamide is generally well-tolerated and offers significant benefits for delaying disease progression.

At Crossroads Urology

At Crossroads Urology, Darolutamide is a preferred treatment for patients with non-metastatic castration-resistant prostate cancer. Our providers prioritize therapies that maximize effectiveness while minimizing side effects, ensuring the best possible outcomes for our patients.

Conclusion

Darolutamide [Nubeqa] is an innovative and effective treatment for advanced prostate cancer, offering a balance of efficacy and safety. Contact Crossroads Urology today to learn more about this advanced therapy and how it can benefit you.